Search NEPH
NEPHROS INC
Nasdaq · CIK 1196298
Last close3.67
Daily change+0.00 (0.00%)
10 Years gain+10.21%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NEPH · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
86.2Momentum
87.5Acceleration
92.5Confidence
91.0Annual Revenue16
Quarterly Revenue57
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth24.0 / 25
Quality20.4 / 25
Capital Efficiency17.9 / 20
Balance Sheet15.0 / 15
Shareholder Economics4.5 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.3787 percentage points.
Operating leverageOperating margin improved by 7.49 percentage points.
ROIC expansionROIC improved by 14.8273 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM34.56%OK
Revenue CAGR 3Y23.5%OK
Gross Margin62.36%OK
Operating Margin9.17%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC17.86%OK
Incremental Operating Margin 3Y60.64%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y4.68%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $18.79M | $11.63M | $1.15M | n/a | n/a | 61.87% | 6.1% | n/a | 15.1% | 10.97M |
| 2025 FY Dec 31, 2024 | $14.16M | $8.72M | $6,000.00 | -$492,000.00 | -$547,000.00 | 61.59% | 0.04% | -3.86% | 0.11% | 10.6M |
| 2024 FY Dec 31, 2023 | $14.24M | $8.41M | -$1.59M | $827,000.00 | $752,000.00 | 59.03% | -11.19% | 5.28% | -41.4% | 10.39M |
| 2023 FY Dec 31, 2022 | $9.98M | $4.73M | -$4.34M | -$3.23M | -$3.37M | 47.43% | -43.46% | -33.79% | -96.55% | 10.3M |
| 2022 FY Dec 31, 2021 | $10.22M | $5.63M | -$3.25M | -$1.42M | -$1.45M | 55.13% | -31.83% | -14.22% | -51.74% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $20.41M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-036851, 0001493152-25-021061 |
| Revenue Growth TTM | 34.56% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-036851, 0001493152-25-021061 |
| Revenue CAGR 3Y | 23.5% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-009848 |
| Revenue CAGR 5Y | 17.02% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-009848 |
| Gross Profit CAGR 3Y | 34.94% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-009848 |
| Operating Income Growth | 634.12% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001493152-26-036851, 0001493152-25-021061 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 62.36% | Gross Profit / Revenue | OK | 0001493152-26-036851, 0001493152-25-021061 |
| Operating Margin | 9.17% | Operating Income / Revenue | OK | 0001493152-26-036851, 0001493152-25-021061 |
| ROIC | 17.86% | NOPAT / Average Invested Capital | OK | 0001493152-26-036851, 0001493152-25-021061 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-036851 |
| Current Ratio | 4.07x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.84 | Revenue / Diluted Shares | OK | 0001493152-26-036851, 0001493152-25-021061 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |